Overactive Bladder Treatment Market to Reach USD 5.45 Billion by 2032, Driven by Aging Population, Drug Innovation, and Rising Awareness
According to Research by SNS Insider, U.S. Overactive Bladder Treatment Market Continues Steady Growth Amid High Prevalence of Urinary Disorders and Increased R&D Initiatives by Key Pharma Players.
Austin, June 04, 2025 (GLOBE NEWSWIRE) -- Overactive Bladder Treatment Market Size & Growth Analysis:
According to SNS Insider, the Overactive Bladder Treatment Market size was estimated at USD 3.63 billion in 2023 and is expected to reach USD 5.45 billion by 2032, at a CAGR of 4.64% during the forecast period of 2024-2032.
The overactive bladder treatment market has been growing steadily owing to the increasing number of conditions associated with OAB and the availability of treatment modalities. It is due to rising aging populations, improved levels of diagnosis, and developing pharma treatments, which are some of the factors driving growth in the market. Furthermore, innovations in drugs are becoming safer and more potent, and the expanding access to healthcare facilities also remains a driving factor for the growth of the market globally.Get a Sample Report of Overactive Bladder Treatment Market@ https://www.snsinsider.com/sample-request/2586
The U.S. overactive bladder treatment market was estimated at USD 1.05 billion in 2023 and is expected to reach USD 1.56 billion by 2032, at a CAGR of 4.53% during the forecast period of 2024-2032. The United States had the largest share in the North American overactive bladder treatment market owing to its high incidence of OAB conditions, well-developed healthcare infrastructure, and extensive presence of top pharma players. The nation is also favored by increased awareness and early detection, thus leading to higher treatment adoption.
Overactive Bladder Treatment Market Report Scope
Report Attributes
Details
Market Size in 2023
US$ 3.63 billion
Market Size by 2032
US$ 5.45 billion
CAGR
CAGR of 4.64% From 2024 to 2032
Base Year
2023
Forecast Period
2024-2032
Historical Data
2020-2022
Key Segments
By Disease Type (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder)By Type (Anticholinergics, Neuromodulation, Mirabegron, Botox, Other)By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
Segmentation Insights
By Type, Mirabegron Segment Leads the Market
Mirabegron dominated the overactive bladder treatment market in 2023 with a 26% market share, as it was more potent than conventional anticholinergic medications and had a better safety profile. Mirabegron (Myrbetriq), the first β3-adrenoceptor agonist on the market, is an alternative to antimuscarinics that has fewer serious side effects (e.g., xerostomia and constipation associated with antimuscarinics). Its once-daily dosing and improved patient compliance make it easier for patients to take while also benefiting doctors.
By Disease Type, Idiopathic OAB Segment dominated the Overactive Bladder Treatment Market
In 2023, the idiopathic overactive bladder segment accounted for the largest share in the market with 76% market share because it is highly prevalent and has a mysterious etiology, which demands treatment. Compared to neurogenic OAB, idiopathic conditions are without any recognizable neurological reason, thus prevailing more in the general population, particularly the elderly. The increasing population of elderly individuals, coupled with lifestyle and rising awareness rates, has accelerated diagnosis rates. Since drug treatments such as Mirabegron and antimuscarinics are widely prescribed for idiopathic patients, this category is still creating significant demand for the drugs as well as urological visits.
By Distribution Channel, the Retail Pharmacies Segment Dominated the Overactive Bladder Treatment Market in 2023
The retail pharmacies segment led the market by 76% market share in 2023 because it was easily accessible, convenient, and could directly reach patients. The majority of overactive bladder drugs, such as Mirabegron and antimuscarinics, are prescribed and dispensed via retail pharmacies. Retail pharmacies offer direct counseling, assist in medication adherence, and typically serve as the first point of contact for chronic disease management.
Need Any Customization Research on Overactive Bladder Treatment Market, Enquire Now@ https://www.snsinsider.com/enquiry/2586
Major Players Analysis Listed in this Report are:
Astellas Pharma Inc.
Pfizer Inc.
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Medtronic Plc.
Viatris Inc.
Hisamitsu Pharmaceutical Co. Inc.
Johnson & Johnson
Endo Pharmaceuticals Inc.
Alembic Pharmaceuticals Limited
Axonics Modulation Technologies Inc.
Apotex Inc.
Aurobindo Pharma Limited
Cogentix Medical Inc.
Intas Pharmaceuticals Ltd.
Macleods Pharmaceuticals Ltd.
Mylan N.V.
Sanofi
Sumitomo Pharma America Inc. (Urovant Sciences)
Alembic Pharmaceuticals Limited.
North America Leads the Overactive Bladder Treatment Market, Asia Pacific is the Most Rapidly Growing Region
North America dominates the overactive bladder treatment market with a 37% market share in 2023 due to its established healthcare infrastructure, high patient awareness, and dominant access to advanced therapeutics. The region has the development of huge pharmaceutical companies along with an increasing population of elderly adults, who are more susceptible to urological conditions.
Asia Pacific is expected to observe the fastest growth in the overactive bladder treatment market during the forecast period due to growing healthcare spending, rising awareness, and an expanding geriatric population. There are lots of investments in the field of healthcare around the regions of China, India, and Japan.
Buy a Single-User PDF of Overactive Bladder Treatment Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/2586
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
June 2025's Top Stock Picks Possibly Priced Below Estimated Value
As the major U.S. stock indices, including the S&P 500 and Dow Jones, continue to post gains amid strong economic data and easing tariff concerns, investors are increasingly on the lookout for opportunities that may be undervalued in this buoyant market. Identifying stocks potentially priced below their estimated value can offer a strategic advantage, especially when supported by robust corporate earnings and favorable economic indicators. Name Current Price Fair Value (Est) Discount (Est) Verra Mobility (VRRM) $24.38 $47.89 49.1% Redwire (RDW) $17.68 $35.10 49.6% Peoples Financial Services (PFIS) $47.56 $93.66 49.2% Pagaya Technologies (PGY) $16.75 $33.36 49.8% MetroCity Bankshares (MCBS) $27.31 $53.06 48.5% Lyft (LYFT) $15.53 $30.52 49.1% Lincoln Educational Services (LINC) $22.57 $44.02 48.7% First Internet Bancorp (INBK) $22.58 $43.85 48.5% Central Pacific Financial (CPF) $26.30 $51.99 49.4% Arrow Financial (AROW) $25.41 $49.74 48.9% Click here to see the full list of 156 stocks from our Undervalued US Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: Ltd. operates a cloud-based web development platform serving registered users and creators globally, with a market cap of $8.57 billion. Operations: The company's revenue primarily stems from its Internet Software & Services segment, which generated $1.81 billion. Estimated Discount To Fair Value: 10.1% is trading at US$153.25, slightly below its estimated fair value of US$170.37, indicating it may be undervalued based on cash flows. The company reported strong earnings growth with Q1 2025 revenue at US$473.65 million and net income of US$33.77 million, reflecting robust financial performance despite a high level of debt. Its innovative product launches like Wixel and strategic partnerships further support its growth potential in the evolving tech landscape. In light of our recent growth report, it seems possible that financial performance will exceed current levels. Unlock comprehensive insights into our analysis of stock in this financial health report. Overview: Albemarle Corporation offers energy storage solutions globally and has a market cap of approximately $7.02 billion. Operations: The company's revenue is derived from three main segments: Ketjen ($1.02 billion), Specialties ($1.33 billion), and Energy Storage ($2.74 billion). Estimated Discount To Fair Value: 17.7% Albemarle, trading at US$58.64, is undervalued compared to its estimated fair value of US$71.23. Despite a drop in sales to US$1.08 billion for Q1 2025 from the previous year, net income rose significantly to US$41.35 million, highlighting improved profitability. However, its dividend yield of 2.76% is not well supported by earnings or free cash flows, and it faces challenges with low projected return on equity and being dropped from the FTSE All-World Index. Our expertly prepared growth report on Albemarle implies its future financial outlook may be stronger than recent results. Click here to discover the nuances of Albemarle with our detailed financial health report. Overview: Sociedad Química y Minera de Chile S.A. is a global mining company with a market cap of approximately $9.15 billion. Operations: The company's revenue segments include Potassium ($249.68 million), Industrial Chemicals ($75.14 million), Iodine and Derivatives ($983.18 million), Lithium and Derivatives ($2.20 billion), and Specialty Plant Nutrition ($946.42 million). Estimated Discount To Fair Value: 24.1% Sociedad Química y Minera de Chile is trading at US$32.30, significantly below its estimated fair value of US$42.53, indicating it is undervalued by over 20%. Despite a slight decline in Q1 2025 sales to US$1.04 billion, net income improved substantially to US$137.53 million from a loss last year. While earnings are expected to grow at a robust rate of 26.12% annually, the dividend yield of 6.54% lacks sufficient coverage from earnings or free cash flows and the company maintains a high debt level. Our earnings growth report unveils the potential for significant increases in Sociedad Química y Minera de Chile's future results. Dive into the specifics of Sociedad Química y Minera de Chile here with our thorough financial health report. Click through to start exploring the rest of the 153 Undervalued US Stocks Based On Cash Flows now. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include WIX ALB and SQM. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Datadog (NasdaqGS:DDOG) Approves Amendment to Certificate of Incorporation at AGM
Datadog recently approved changes to its Certificate of Incorporation, reflecting a strategic corporate governance update. Over the last month, the company's share price rose by about 15%, aligning with broader market trends where major indexes like the S&P 500 continued to post gains. The strength in overall market sentiment, driven by solid economic data and eased concerns over tariffs, likely provided a favorable backdrop. While the amendments to Datadog's corporate bylaws may have added some weight to investor confidence, the company's price move generally mirrored the robust performance of the tech sector. We've discovered 1 weakness for Datadog that you should be aware of before investing here. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Datadog's recent updates to its Certificate of Incorporation may contribute to an enhanced perception of corporate governance, potentially fostering an environment conducive to increased investor confidence. Aligning with technological advancements, Datadog's robust adoption of AI integrations and strategic acquisitions supports a narrative of growth, especially as these initiatives align with buoyant market conditions. As total shareholder returns indicate, Datadog's shares delivered a substantial 55.99% return over a five-year period. However, amid the past year's 11% performance that matched the broader U.S. market, the company's longer-term trajectory remains significant for current and prospective stakeholders. Despite the optimism surrounding its product innovations and acquisitions, the company's share price movement in relation to the consensus price target suggests a broader context of challenges and expectations. Currently trading at US$118.66, the share price remains approximately 12.5% below the consensus analyst price target of US$135.55, highlighting both growth potential and market skepticism. The news and corporate actions reinforce potential pathways for increased revenue and profitability, where forecasts anticipate revenue growth to US$4.90 billion within three years. However, expected earnings growth juxtaposes potential financial pressures from increased costs and international market expansion, underscoring an essential balance in achieving projected outcomes. Insights from our recent valuation report point to the potential undervaluation of Datadog shares in the market. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:DDOG. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
What is the bond market and why is everybody so worried about it?
The bond market doesn't make headlines nearly as often as its more exciting cousin, the stock market, but when it does, look out. At least twice in 2025, bond investors have reacted negatively to U.S. President Donald Trump's policies, spooked first by his trade war and more recently by the growing U.S. government debt. Those join a list of other recent bond market tantrums that suggest investors have growing concerns about the state of government finances around the world. But just what is the bond market, how does it work and why is it such a problem when investors get jittery about it? The Financial Post explains. The bond market is a financial market where governments, companies and investors can issue, buy and sell debt in the form of — you guessed it — bonds. For governments, selling a new bond raises the funds needed to finance public spending, while a business might use the proceeds for corporate operations or an acquisition. In return, bonds provide investors with periodic interest payments, usually at a fixed interest rate, and guarantee the repayment of the principal at maturity. Government bonds can come in a range of durations from months all the way up to decades. For example, U.S. government debt ranges from one-month Treasury bills to 30-year Treasury bonds. Investors are especially focused on the U.S. bond market because it is the largest in the world, worth about US$47 trillion. This accounts for about 40 per cent of the US$142 trillion global bond market as of 2025, according to the Securities Industry and Financial Markets Association, a U.S. industry trade group. As of the fourth quarter of 2024, investors held US$28 trillion of government debt in Treasuries. Investors buy government bonds because they are seen as safe, especially in contrast to stocks, which can carry more risk, especially during economic turbulence. Bonds pay out steady interest, and there is little risk the government of a major economy such as the U.S. will not repay the principal at maturity — or at least that's the theory. In reality, investors increasingly appear to be questioning whether government bonds, in particular those issued by the U.S., are such a safe bet. Carl Gomez, chief economist and head of market analytics for CoStar Group, said the bond market, like any other market for financial assets, depends on buyers and sellers making trades based on their expectations regarding market conditions. And some recent decisions by the U.S. government have investors feeling like they are taking on more risk with bonds, he said. When Trump unveiled his plan for massive tariffs on other countries on 'Liberation Day' in April, it sent shockwaves through the stock market. Although normally investors would buy bonds as a counterweight to equity risk, something unexpected happened. There was a selloff in the bond market as well, signalling that buyers were losing confidence in the U.S. as a safe place to store their money. The 10-year Treasury yield spiked from less than four per cent on April 4 to 4.5 per cent on April 8, while the 30-year yield topped five per cent. 'People are worried the independence of the Fed could be eroded to some extent, people are worried that the U.S. administration's policies have not been friendly to the allies or to the providers of capital for the U.S. market,' said Jason Daw, the head of North American rates strategy at Royal Bank of Canada (RBC) Capital Markets. 'This has led the market to believe that (foreign) investors are going to be investing less in the U.S and maybe more in their domestic markets.' And with the U.S.'s massive debt, investors question the government's fiscal prudence, weakening demand for U.S. bonds. Trump's 'big, beautiful' tax bill lead to the second big spike in yields this year. Introduced in May, the bill included extended tax cuts and an increase to the national debt ceiling, and would add nearly US$4 trillion to America's US$36 trillion in debt if passed. In the immediate aftermath of the tax bill announcement on May 22, the 10-year yield closed at 4.58 per cent, its highest level since 2023. To make matters worse, credit rating agency Moody's Corp. downgraded America's credit rating due to the country's inability to manage its ballooning debt. Following that up, there was tepid demand at a US$16 billion 20-year Treasury bond auction, another key indicator of the bond market's woes, pushing yields to 5.1 per cent. 'When the government goes to borrow, they auction up the bonds, and get the money from the Treasury,' Gomez said. 'If there are fewer buyers, then that price is going to come down, and the yields will need to go up on those bonds to make them sellable.' When people talk about trouble in the bond market, they often talk about yields spiking. The yield on a bond is how much you would expect to earn on your money per year if you held the bond through to maturity, including both interest payments and price return. While the interest payment on a bond is usually fixed, yields adjust to prevailing expectations about where interest rates are heading. For example, if investors think they will be able to buy a new bond at an interest rate of five per cent, they aren't likely to want an existing bond with an interest rate of only four per cent. So the price of that older bond falls. The big thing to remember is that yields and prices are inversely related: If yields go up or spike, it means the value of the bonds people are holding goes down. 'Similar to how the value of a stock or the equity market could change, the value of bonds changes depending on people's expectations of future interest rates and depending on when you purchase the bond (which could be) at a value that is above or below its maturity level,' said Daw. If bond buyers are concerned that the U.S. fiscal position is deteriorating, they are likely going to want a higher return to offset the risk of lending to Uncle Sam. So, yields go up, and prices go down. Bond yields have been rising across the globe — a striking reversal in a long-term trend of declining yields that persisted over the past 20 to 30 years thanks to modest inflation and economic stability. With inflation higher post-COVID and due to economic jitters from the U.S.-initiated trade war, there is less demand for especially long-term government bonds globally, making it more expensive for governments to borrow. If the U.S. has trouble selling its bonds at rates that allow it to service its debt, it could be forced to raise interest rates to higher and higher levels to placate investors seeking compensation for taking on the greater risk. Increasing interest rates could create a vicious cycle of higher rates making it more expensive for the government to service its debt, leading to bigger deficits and more debt, producing greater risk that buyers will want to be compensated for with higher interest rates. Most importantly, the U.S. relies on the sale of its Treasury bonds to fund its operations. If buyers don't want to buy bonds, the government could struggle to pay its bills, especially if there aren't sufficient tax revenues, Gomez said. 'Ultimately, it can lead to a financial crisis,' he said. 'It circles down across the whole financial system into the real economy.' Gomez pointed to Greece as an example. The country toppled into a government debt crisis in 2007, exacerbated by the global financial crisis, and struggled to recover. Major financial rating agencies flagged Greek bonds with 'junk' status in 2010. The country's unemployment rate hit a record 28 per cent in 2014, and poverty and homelessness snowballed. 'This doesn't usually happen to a well-developed country like the United States, given its position in the world,' Gomez said, noting the Fed could step in and be 'the buyer of last resort.' Still, this could lead to major inflation risks caused by 'printing money' and potentially call into question America's long-term debt sustainability, which would result in higher interest rates over the long run, he said. Although Canada's bond market typically follows the same direction as its southern neighbour, Gomez said it has hit a resistance point due to the Bank of Canada cutting interest rates out of step with the U.S. Federal Reserve. Canadian bond yields are getting tugged upward, influenced by what is occurring in the U.S., but they are also being pulled down by the central bank. 'Everybody probably expected at the end of last year that we'd see lower interest rates, lower mortgages,' Gomez said. 'But what's really happening is that the bond market and bond yields in Canada are just going sideways.' If the Fed starts cutting rates more than the Bank of Canada, Daw said it is likely the Canadian bond market will underperform the U.S. Treasury market over the next six to 12 months. Canada's central bank is in a tight spot, as it weighs the upside risks to inflation against the downside risks to growth brought on by U.S. tariffs. The other factor weighing on Canadian market sentiment is the expectation that the federal government and provinces will be issuing plenty of bonds this year to increase spending to support the economy through the trade war. When the supply of bonds goes up, this puts downward pressure on bond prices and upward pressure on bond yields. Canada's debt position doesn't look as grim as the U.S., but it is growing. The U.S. debt to gross domestic product (GDP) ratio was 123 per cent in 2024, while Canada's amounted to 110.8 per cent — but Canada's debt to GDP ratio has been on an upward path since 2022 and is markedly higher than its pre-pandemic levels (where it hovered around the 90 per cent range). Why everyone is worried about the bond market — especially Donald Trump Bond market volatility spells trouble for investors Gomez predicted that the Canadian bond market will outperform the U.S. but added that inflation and global factors will still influence yields. 'The thing about the U.S. is that it is still the centre of the capital markets across the world,' said Gomez. 'So, what happens in the U.S. invariably starts impacting the rest of the world.' • Email: slouis@ Sign in to access your portfolio
